ImmunoGen, Inc.
ImmunoGen, Inc. (IMGN) Stock Overview
Explore ImmunoGen, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
8.7B
P/E Ratio
-35.54
EPS (TTM)
$-0.28
ROE
-1.43%
IMGN Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of ImmunoGen, Inc. (IMGN) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
Our forecasting models predict significant price movements, with a 12-month target of $70.78.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -35.54 and a market capitalization of 8.7B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Company Profile
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.
Mark Joseph Enyedy
277
830 Winter Street, Waltham, MA
1989